

5th

MEETING OF TRANSLATIONAL HEPATOLOGY

**October
5th & 6th
2023**

Sevilla

COURSE DIRECTORS

Edilmar Alvarado (Barcelona)
Manuel D. Gahete (Córdoba)
Douglas Maya (Sevilla)



FACULTY

- Agustín **Albillos** (Madrid)
Rocío **Aller** (Valladolid)
Edilmar **Alvarado** (Barcelona)
Javier **Ampuero** (Sevilla)
Raúl **Andrade** (Málaga)
María **Arechederra** (Pamplona)
Patricia **Aspichueta** (Bilbao)
Jesús **Bañales** (San Sebastián)
Rafael **Bañares** (Madrid)
Ana **Blas** (Valencia)
Esther **Caparrós** (Alicante)
Teresa **Cardoso** (Bilbao)
Antonio **Carrillo** (Sevilla)
Joan **Clària** (Barcelona)
Javier **Cubero** (Madrid)
Alberto **Díaz-Ruiz** (Madrid)
Maite G. **Fernández-Barrena** (Pamplona)
Anabel **Fernández-Iglesias** (Barcelona)
Sonia **Fernández-Veledo** (Tarragona)
Rubén **Francés** (Alicante)
Manuel D. **Gahete** (Córdoba)
Rocío **Gallego** (Sevilla)
Jordi **Gracia** (Barcelona)
Virginia **Hernández-Gea** (Barcelona)
Manuel **Irimia** (Barcelona)
Sabela **Lens** (Barcelona)
Mariluz **Martínez-Chantar** (Derio)
Douglas **Maya** (Sevilla)
Beatriz **Mínguez** (Barcelona)
Nuria **Montserrat** (Barcelona)
Rocío **Muñoz-Hernández** (Sevilla)
Rubén **Nogueiras** (Santiago de Compostela)
Matxus **Perugorria** (San Sebastián)
Bruno **Ramos** (Murcia)
María **Rescigno** (Milan, Italy)
Mar **Riveiro** (Barcelona)
Manuel **Rodríguez Perálvarez** (Córdoba)
Manuel **Romero** (Sevilla)
Guadalupe **Sabio** (Madrid)
Pau **Sancho** (Barcelona)
Juan **Turnes** (Pontevedra)
Meritxell **Ventura-Cots** (Barcelona)
Silvia **Vidal** (Barcelona)



#LiverBench23

10:00

Institute of Biomedicine of Seville: IBiS

**SECRETARY OPENING**
Documentation delivery

11:00 - 11:50

Institute of Biomedicine of Seville: IBiS



Welcome + Kahoot answers (i)



12:00 - 13:25

Institute of Biomedicine of Seville: IBiS

**SESSION 1**
MARKERS AND DIAGNOSTIC TOOLS**Chairs:**ROCÍO GALLEGO
IBiS (Sevilla)ESTHER CAPARRÓS
Universidad Miguel Hernández (Alicante)12:00 - 12:15 **Biomarkers in liver disease: the clinician's view**

JAVIER AMPUERO

*Hospital Universitario Virgen del Rocío (Sevilla)*12:15 - 12:30 **Biomarkers in liver disease: the other side of the coin**

MARÍA ARECHEDERRA

*CIMA (Pamplona)*12:30 - 12:45 **Reduce, Reuse and Recycle: can data recycling be useful in biomarker development?**

DOUGLAS MAYA

*IBiS (Sevilla)*12:45 - 13:00 **From exploration to exploitation: how to transform a good idea into a useful health product**

JORDI GRACIA

*IDIBAPS (Barcelona)*13:00 - 13:10 **Selected oral communication****Role of FbIn7 in the dedifferentiation of liver sinusoidal endothelial cells in cirrhotic portal hypertension**

Albert Gibert-Ramos (1) | Sergi Guixé-Muntet (1) | Raül Pastó (1) | Jordi Gracia-Sancho (1)

1- Liver Vascular Biology Lab. IDIBAPS - Hospital Clínic Barcelona - CIBEREHD. Spain.

13:10 - 13:25 **General discussion**

13:30



Central Courtyard Of Virgen del Rocio Hospital



LUNCH

14:15 - 15:00

Central Courtyard Of Virgen del Rocio Hospital



POSTER SESSION



Guided poster tours
SELECTED POSTERS



Nº 10 / Nº 13 / Nº 21 / Nº 23 / Nº 25 / Nº 26 / Nº 27 / Nº 29
Nº 31 / Nº 38 / Nº 44 / Nº 49 / Nº 52 / Nº 55 / Nº 58

15:00 - 16:25

Institute of Biomedicine of Seville: IBIS



SESSION 2

IMMUNE RESPONSE AND INFLAMMATION IN LIVER DISEASES

Chairs:

AGUSTÍN ALBILLOS

Hospital Universitario Ramón y Cajal (Madrid)

ANTONIO CARRILLO

IBIS (Sevilla)

15:00 - 15:15 **The role of the innate immune response in cirrhosis**

SILVIA VIDAL

Hospital de la Santa Creu i Sant Pau (Barcelona)

15:15 - 15:30 **Dysbiosis and immunity in the development of infections in cirrhosis**

RUBÉN FRANCÉS

Universidad Miguel Hernández (Alicante)

15:30 - 15:45 **Neutrophils in the evolution of chronic liver disease**

PAU SANCHO

IDIBAPS (Barcelona)

15:45 - 16:00 **Extracellular vesicles: the new messengers between the immune system and the liver?**

EDILMAR ÁLVARADO

Hospital de la Santa Creu i Sant Pau (Barcelona)

16:00 - 16:10 Selected oral communication**Hepatic LSEctin reduction contributes to proinflammatory T helper 17 cell expansion in patients with decompensated cirrhosis**

Enrique Ángel-Gomis* (1,2) | Sebastián Martínez-López* (1,2) | Isabel Gómez-Hurtado (3) | Anabel Fernández-Iglesias (3,4) | Paula Boix (1) | Javier Morante (5) | Jordi Gracia-Sancho (3,4) | Esther Caparrós (1) | Rubén Francés (1,2,3)

1- Grupo de Inmunobiología Hepática e Intestinal, Dpto. Medicina Clínica, Universidad Miguel Hernández, San Juan, Alicante, España. | 2- IIS ISABIAL, Hospital General Universitario de Alicante, Alicante, España. | 3- CIBERehd, Instituto de Salud Carlos III, Madrid, España. | 4- Liver Vascular Biology Research Group, Fundació de Recerca Clínic Barcelona-IDIBAP, Barcelona, España. | 5- Instituto de Neurociencias, Universidad Miguel Hernández-CSIC, Alicante, España.

16:10 - 16:25 General discussion**16:25 - 17:50**

Institute of Biomedicine of Seville: IBiS

**SESSION 3****HOW FAR IS THE REVERSION OF LIVER DISEASE IN THE ERA OF ETIOLOGICAL TREATMENTS?****Chairs:****MAR RIVEIRO***Hospital Universtiaro Vall d'Hebron (Barcelona)***ANABEL FERNÁNDEZ-IGLESIAS***IDIBAPS (Barcelona)***16:25 - 16:40 Reversal of liver damage: fact or fiction?****MANUEL RODRÍGUEZ PERÁLVAREZ***Hospital Reina Sofía (Córdoba)***16:40 - 16:55 Therapeutic AXIS for the reversal of liver fibrosis****ANA BLAS***Universidad de Valencia (Valencia)***16:55 - 17:10 TRF Patterns and Reversal of Metabolic Hepatic Steatosis****ALBERTO DÍAZ-RUIZ***IMDEA Food Institute (Madrid)***17:10 - 17:25 Monitoring patients after HCV cure, how long is enough?****SABELA LENS***Hospital Clinic (Barcelona)*

17:25 - 17:35 **Selected oral communication**

Efficacy of dietary and physical activity intervention in MetALD

Olga Estévez-Vázquez (1) | Raquel Benedé-Ubieto (1,2) | Héctor Leal-Lassalle (1) | Clémence Baron (3) | Javier Vaquero (4,5,6) | Rafael Bañares (4,5,6) | Francisco Javier Cubero (1,4,5) | Yulia A. Nevzorova (1,4,5)

1- Department of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University of Madrid, Madrid, Spain | 2- Department of Physiology, Genetics and Microbiology, Faculty of Biology, Complutense University of Madrid, Madrid, Spain | 3- Polytech Angers, Département Génie Biologique et Santé, Angers, France | 4- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain | 5- Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28009 Madrid, Spain | 6- Servicio de Aparato Digestivo, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.

17:35 - 17:50 **General discussion**

18:00 - 19:00

IBIS Terrace 

ROUND TABLE

— Coffee and snacks will be served —

Tips to survive and thrive your research

RESEARCH TOPICS

Clinical research paths

RAFAEL BAÑARES - Hospital Gregorio Marañón (Madrid)

Fundamental research paths

MATXUS PERUGORRIA - Instituto Biodonostia (San Sebastián)

Gender, family conciliation and science

VIRGINIA HERNÁNDEZ-GEA - Hospital Clínic (Barcelona)

From Spain to Europe. Lessons learned

NURIA MONTSERRAT - Institute for Bioengineering of Catalonia (IBEC), ICREA (Barcelona)

Science and social media

JUAN TURNES - Complejo Hospitalario Universitario de Pontevedra (Pontevedra)

20:30

LEISURE ACTIVITY AND DINNER

08:30 - 09:55

Institute of Biomedicine of Seville: IBiS

**SESSION 4
BEYOND OMICS APPROACHES****Chairs:****MAITE G. FERNÁNDEZ-BARRENA**
*CIMA (Pamplona)***BEATRIZ MÍNGUEZ**
*Hospital Universitario Vall d'Hebron (Barcelona)***08:30 - 08:45 Importance of omic approaches in the study of liver diseases****JOAN CLÀRIA**
*Hospital Clínic (Barcelona)***08:45 - 09:00 The hidden value of next-generation sequencing****MANUEL IRIMIA**
*CRG (Barcelona)***09:00-09:15 Squeezing proteomic data to unveil novel pathologic pathways in liver diseases****MANUEL D. GAHETE**
*IMIBIC (Córdoba)***09:15 - 09:30 Applying omic approaches to understand less prevalent (rare) liver diseases****JESÚS BAÑALES**
*Instituto Biodonostia (San Sebastián)***09:30 - 09:40 Selected oral communication****ASO-Mediated Inhibition of Degs1 Aggravates Inflammation and Hepatic Fibrosis in Mice by Increasing Free Cholesterol Storage**Oscar Pastor (1) | Bohdan Babiy (1) | Diego Saenz de Urturi (2) | Enric Esplugues (2) | Inmaculada Ruz-Maldonado (2) | Pablo Fernández-Tussy (2) | Karla Cevallos (2) | Sue Murray (3) | Yajaira Suárez (2) | Carlos Fernández-Hernando (2)
1- Hospital Universitario Ramón y Cajal - Irycis, Madrid (Spain) | 2- Yale University School of Medicine, New Haven, CT (USA) | 3- Ionis Pharmaceuticals, Inc. Carlsbad, CA (USA).**09:40 - 09:55 General discussion**

10:00 - 11:45

Institute of Biomedicine of Seville: IBiS



SESSION 5

IMPACT OF TOXIC AND METABOLIC FACTORS ON THE PROGRESSION OF CHRONIC LIVER DISEASE

Chairs:

Rocío ALLER

Hospital Clínico de Valladolid (Valladolid)

Rocío MUÑOZ-HERNÁNDEZ

Hospital Universitario Virgen del Rocío (Sevilla)

10:00 - 10:30 Diet, weight and other metabolic traits

To your left:

MANUEL ROMERO - *Hospital Universitario Virgen del Rocío (Sevilla)*

To your right:

RUBÉN NOGUEIRAS - *Universidad de Santiago de Compostela (Santiago de Compostela)*

10:30 - 11:00 Alcohol: Is there a “healthy” use or is it always a toxic abuse?

To your left:

MERITXELL VENTURA-COTS - *Hospital Universitario Vall d'Hebron (Barcelona)*

To your right:

JAVIER CUBERO - *Universidad Complutense de Madrid (Madrid)*

11:00 - 11:30 DILI and other risk factors associated with progression

To your left:

RAÚL ÁNDRADE - *Hospital Virgen de la Victoria (Málaga)*

To your right:

PATRICIA ÁSPICHUETA - *Facultad de Medicina y Enfermería [UPV] (Bilbao)*

11:30 - 11:45 General discussion

11:45 - 12:15

COFFEE BREAK



IBiS Terrace



12:15 - 13:40

Institute of Biomedicine of Seville: IBiS

**SESSION 6
INTERORGAN CROSSTALK****Chairs:****MANUEL D. GAHETE**

IMIBIC (Córdoba)

TERESA CARDOSO

Biobizkaia Hri (Bilbao)

12:15 - 12:30 Mitochondria, Gut, and Liver Diseases: Exploring Connections and Therapeutic Approaches**MARILUZ MARTÍNEZ-CHANTAR**

CICbioGUNE (Bilbao)

12:30 - 12:45 The liver-adipose tissue couple: in sickness and in health**SONIA FERNÁNDEZ-VELEDO**

Fundación Instituto de Investigación Sanitaria Pere Virgili (Tarragona)

12:45 - 13:00 How important is the heart to the liver?**GUADALUPE SABIO**

CNIC (Madrid)

13:00 - 13:15 Muscle, the forgotten travel friend of the liver**BRUNO RAMOS-MOLINA**

Instituto Murciano de Investigación Biosanitaria (Murcia)

13:15 - 13:25 Selected oral communication**Maternal high fat diets based on olive oil protect female but not male offspring against metabolic dysfunction-associated steatotic liver**Lucía López Bermudo (1,2) | Amparo Luque Sierra (1) | Antonio Cárdenas García (1,2) | Blanca Escudero López (1,2) | M^a José Robles Frias (3) | Genoveva Berná Amorós (1,2) | Douglas Maya Miles (4,5) | Franz Martín Bermudo (1,2)

1- Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), Seville, Spain. | 2- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain. | 3- Pathology Department, Hospital Universitario Virgen del Rocío, Seville, Spain. | 4- Institute of Biomedicine of Seville (IBiS), SeLiver Group, Virgen del Rocío University Hospital/CSIC/University of Seville. | 5- UCM Digestive Diseases & CIBERehd, Virgen del Rocío University Hospital, Seville.

13:25 - 13:40 General discussion

13:40 - 14:40

Institute of Biomedicine of Seville: IBiS



STATE OF THE ART LECTURE

MARIA RESCIGNO

RCSS Humanitas Research Hospital & Humanitas University (Milan, Italy)

Maria Rescigno is full professor and vice rector for research at Humanitas University, as well group leader at Humanitas Research Hospital, in Milan, where she leads the Mucosal Immunology and Microbiota Lab. She was the first to show that dendritic cells actively participate to bacterial uptake in the gut and the existence of a gut vascular barrier that resembles the blood brain barrier. She authors more than 200 publications in high impact journals such as Science, Nature Immunology, Nature Medicine, Journal of Experimental Medicine and Science Translational Medicine. She was nominated EMBO young investigator in 2007, elected EMBO member in 2011 and since 2019 she is member of the EMBO council. Her research activity has been funded, among others, by three ERC grants (starting, proof-of-concept and consolidator). In 2016 she founded Postbiotix, a start-up that exploits microbiota-derived metabolites as new pharmaceutical agents.

14:40 - 15:20

Institute of Biomedicine of Seville: IBiS



CLOSING CEREMONY

Kahoot answers: The final



Prizes and Awards



POSTER SESSION SESSION

ÁREA TEMÁTICA	POSTERS
Cáncer de hígado	1 - 23
Complicaciones de la cirrosis y trasplante hepático	24 - 30
Enfermedades colestásicas y autoinmunes	31 - 33
Enfermedades vasculares hepáticas, genéticas, inmunológicas y DILI	34 - 37
Hepatopatía alcohólica y enfermedad hepática metabólica	38 - 61



POSTER TOUR

SELECTED POSTERS

Nº 10 / Nº 13 / Nº 21 / Nº 23 / Nº 25 / Nº 26 / Nº 27 / Nº 29

Nº 31 / Nº 38 / Nº 44 / Nº 49 / Nº 52 / Nº 55 / Nº 58




C. Antonio Maura Montaner, 41013 Sevilla



C. Antonio Maura Montaner, 41013 Sevilla



Av. Manuel Siurot, 43, 41013 Sevilla



CÁNCER DE HÍGADO

Póster: 1**Sensitization of cholangiocarcinoma to chemotherapy by β -caryophyllene oxide-induced BCRP inhibition**

Sara Ortiz-Rivero (1,2) | Ana Peleteiro-Vigil (1) | Lorena Abete (3) | Silvia Di Giacomo (3) | Jose J.G. Marin (1,2) | Oscar Briz (1,2)

1- *Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain.* | 2- *Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Carlos III National Institute of Health, Madrid, Spain.* | 3- *Department of Physiology and Pharmacology "V. Erespamer", Sapienza University of Rome, Rome, Italy.*

Póster: 2**Role of miRNA-141 in the development of chemoresistance in liver cancer**

Nazaret Hortelano Hernández (1,2) | Nuria Cruz Navarro (1) | Marta García-Gallego (1) | Beatriz Sánchez de Blas (1,2,3) | Alvaro G. Temprano (1,2,3) | Pedro M. Rodrigues (3,4,5) | Xavier Buqué (6) | Maitane Asensio (2) | María A. Serrano (1,2,3) | Óscar Briz (1,2,3) | Elisa Lozano (1,2,3) | Marta R. Romero (1,2,3) | José J. G. Marin (1,2,3)

1- *Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca.* | 2- *Institute of Biochemical Research of Salamanca (IBSAL), Salamanca.* | 3- *National Institute for the Study of Liver&Gastrointestinal Diseases (CIBERehd), Madrid.* | 4- *Department of Liver&Gastrointestinal Diseases, Biodonostia Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian.* | 5- *IKERBASQUE, Basque Foundation for Science, Bilbao.* | 6- *Department of Physiology, Medicine and Nursing Faculty, University of the Basque Country (UPV/EHU).*

Póster: 3**Novel Regulatory Mechanisms of the Transforming Growth Factor β Signaling Pathway by the Histone Methyltransferase G9a**

Borja Castelló-Urbe (1) | Amaya Lopez-Pascual (2,3) | Jose Maria Herranz (1,4) | Elena Adan-Villaescusa (1) | Ainara Irigaray-Miramón (1) | Maria Ujue Latasa (1) | Iker Uriarte (1,4) | Maria Arechederra (1,3,4) | Isabel Fabregat (4,5,6) | Carmen Berasain (1,4) | Maite G. Fernandez-Barrena (1,3,4) | Matias A. Avila (1,3,4)

1- *Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.* | 2- *Hepatology Unit, CCUN, Navarra University Clinic, Pamplona, Spain.* | 3- *Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain.* | 4- *CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.* | 5- *TGF- β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.* | 6- *Department of Physiological Sciences, Faculty of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain.*

CÁNCER DE HÍGADO

Póster: 4

NOX4 and NOX1 act in concert to allow TGFbeta-induced transactivation of human hepatic stellate cells into cancer-associated fibroblasts

Josep Amengual (1,2) | Ester Gonzalez-Sanchez (1,2,3) | Noel P Fuste (1) | Isabel Fabregat (1,2) | Javier Vaquero (1,2,4)

1- TGF- β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. | 2- CIBEREHD, National Biomedical Research Institute on Liver and Gastrointestinal Diseases, Instituto de Salud Carlos III, Madrid, Spain. | 3- Department of Physiological Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Spain. | 4- Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, CSIC-Universidad de Salamanca, Salamanca 37007, Spain.

Póster: 5

Alcohol and hepatitis C virus infection are the main causes of hepatocarcinoma development in the era of total accessibility to direct-acting antivirals

Elena Vargas-Accarino (1,2) | Mónica Higuera (1) | María Buti (1,2,3,4) | Beatriz Mínguez (1,2,3,4)

1- Liver Diseases Research Group, Vall d'Hebron Institut de Recerca (VHIR) | 2- Department of Medicine, Universitat Autònoma de Barcelona (UAB) | 3- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III | 4- Liver Unit, Vall d'Hebron University Hospital

Póster: 6

Effect of Zinc Acexamate treatment in hepatocellular carcinoma in vitro and in vivo models

Mónica Higuera (1) | Elena Vargas-Accarino (1,2) | Sara Galán-Vinagre (1) | Isaac Manjón (1) | María Teresa Salcedo (2,3,4) | Beatriz Mínguez (1,2,5,6)

1- Liver Cancer Research Group, Liver Diseases, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain | 2- Department of Medicine, Campus de la UAB, Universitat Autònoma de Barcelona (UAB), Bellaterra, Cerdanyola del Vallès, Spain | 3- Pathology Department, Hospital Universitario Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain | 4- Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain | 5- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain | 6- Liver Unit, Hospital Universitario Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain

CÁNCER DE HÍGADO

Póster: 7**Modulation of the WNT/ β -Catenin pathway as a potential chemosensitive strategy in cholangiocarcinoma**

Kevin Delgado-Calvo (1) | Oscar Briz Sánchez (1,2) | José J.G. Marín (1,2) | Rocío I.R. Macias (1,2) | Luke Boulter (3) | Elisa Lozano (1,2)

1- *Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain.* | 2- *Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, Madrid, Spain.* | 3- *MRC-Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK*

Póster: 8**Role of the ABC pump MRP3 (ABCC3) in the resistance and sensitization to antitumor drugs in cholangiocarcinoma**

Maitane Asensio (1,2) | Oscar Briz (1,2) | Ricardo Espinosa-Escudero (1) | Ana Peleteiro-Vigil (1) | Elisa Herraiz (1,2) | Oliver Pötz (3,4) | Rocío I. R. Macias (1,2) | Elisa Lozano (1,2) | Jose J.G. Marín (1,2)

1- *Experimental Hepatology and Drug Targeting (HEVEPHARM), IBSAL, University of Salamanca.* | 2- *National Institute for the Study of Liver and Gastrointestinal Diseases (CIBEREhd), Carlos III National Health Institute, Madrid.* | 3- *Signatope GmbH, Reutlingen, Germany.* | 4- *Natural and Medical Sciences Institute at the University of Tuebingen (NMI), Reutlingen, Germany*

Póster: 9**Firma de miRNA de respuesta a Sorafenib: estudios in vitro, in vivo y en dos cohortes de pacientes**

Patricia de la Cruz-Ojeda (1,2,3) | Elena Navarro-Villarán (1,2,3) | Manuela Moreno (4) | Inés Fernández-Luque (4) | M. Fátima Domínguez-Borrero (5) | Concepción Meana (5) | Juan M. Praena-Fernández (6) | Juan M. Falcón-Pérez (3,7) | Álvaro Giráldez (5,8) | Bernhard Brüne (9,10,11,12) | Loreto Boix (3,13) | Tobias Schmid (9) | María Reig (3,13) | María T. Ferrer (5,8) | Jordi Bruix (3,13) | Francisco J. Padillo (3,4,8) | Jordi Muntané (1,2,3)

1- *Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, España* | 2- *Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, España.* | 3- *Centro de Investigación Biomédica en red de Enfermedades Hepáticas y Digestivas (CIBEREHD).* | 4- *Servicio de Cirugía General, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, España.* | 5- *Servicio de Aparato Digestivo, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, España.* | 6- *Departamento Estadística e Investigación Operativa, Universidad de Granada, Granada, España.* | 7- *Exosomes Lab, CIC bioGUNE, Derio, España* | 8- *Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, España.* | 9- *Instituto de Bioquímica I, Facultad de Medicina, Universidad Goethe Frankfurt, Frankfurt, Alemania.* | 10- *Consortio Alemán del*

CÁNCER DE HÍGADO

Cáncer, (DKTK), Partner Site Frankfurt, Frankfurt, Alemania. | 11- Instituto del Cáncer de Frankfurt, Universidad Goethe Frankfurt, Frankfurt, Alemania. | 12- Instituto Fraunhofer de Medicina Traslacional y Farmacología (ITMP), Frankfurt, Alemania. | 13- BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain.

Póster: 10



POSTER TOUR

The E2F2-glycerophosphodiester phosphodiesterase 3 (GDPD3) axis promotes metabolic associated fatty-liver disease and related hepatocellular carcinoma

Maidar Apodaka-Biguri (1) | Nerea Muñoz-Llanes (1) | Daniela Mestre (1) | Francisco Gonzalez-Romero (1) | Igor Aurrekoetxea (1,2) | Beatriz Gómez-Santos (1) | Igotz Delgado (1) | Xabier Buqué (1,2) | Ane Nieva-Zuluaga (1) | Mikel Ruiz de Gauna (1) | Idoia Fernández-Puertas (1) | Paul Gómez-Jauregui (1) | Natalia Sainz-Ramirez (1) | Kendall Alfaro-Jimenez (1) | Ashwin Woodhoo (3,4) | Marta Varela-Rey (5) | Amaia Lujambio (6) | Ana M. Zubiaga (7) | Patricia Aspichueta (1,2,8)

1- Department of Physiology University of the Basque Country UPV/EHU, Faculty of Medicine and Nursing, Leioa, Spain | 2- Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Barakaldo, Spain | 3- Center for Cooperative Research in Bioscience (CIC bioGUNE), Derio, Spain | 4- Ikerbasque, Basque Foundation for Science, Bilbao, Spain | 5- Liver Disease Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), CIBERehd Derio, Spain | 6- Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA | 7- Department of Genetic, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, University of Basque Country UPV/EHU, Leioa, Spain | 8- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Carlos III Health Institute), Madrid, Spain

Póster: 11

Utility of ultra-low-pass whole genome sequencing in bile cfDNA for the management of patients with biliary strictures

María Arechederra (1,2,3) | Carla Rojo (1) | María Rullán (2,4) | María Elizalde (1) | Jose Mari Herranz (1,3) | Daniel Oyón (5) | Juan J Vila (2,4) | María Azkona (1) | Francesco P Marchese (6) | Josepmaría Argemi (1,2,3,6,7) | Maite G Fernández-Barrena (1,2,3) | Jesús Urmán (2,4) | Matías A Ávila (1,2,3) | Carmen Berasain (1,3)

1- Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain. | 2- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. | 3- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Carlos III Health Institute), Madrid, Spain. | 4- Department of Gastroenterology and Hepatology, Navarra University Hospital Complex, Pamplona, Spain | 5- Hospital Universitario de Galdakao, Galdakao (Spain) | 6- Genomics Unit, CIMA Universidad de Navarra, Pamplona, Spain | 7- Internal Medicine Department, Clinica Universidad de Navarra, Pamplona, Spain.

CÁNCER DE HÍGADO

Póster: 12

Novel platinum-based chemotherapeutic agents halt cholangiocarcinoma progression through the induction of inter-strand DNA breaks, preventing DNA repair mechanisms

Irene Olaizola (1) | Mikel Odriozola (2) | Maitane Asensio (3,4) | Paula Olaizola (1,4) | Iván Rivilla (2,5) | Amanda Guimaraes (2) | Francisco J. Caballero-Camino (1) | Elisa Herráez (3,4) | Óscar Briz (3,4) | Pedro M. Rodrigues (1,4,5) | Maria J. Perugorria (1,4,6) | Luis Bujanda (1,4) | Jose J. Garcia-Marin (3,4) | Fernando Cossio (2) | Jesus M. Banales (1,4,5,7)

1- Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), San Sebastian, Spain | 2- Department of Organic Chemistry I, Center of Innovation in Advanced Chemistry (OR-FEO-CINQA), Faculty of Chemistry, University of the Basque Country (UPV/EHU) and Donostia International Physics Center (DIPC), San Sebastian, Spain | 3- Experimental Hepatology and Drug Targeting (HEVEPHARM) Group, Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain | 4- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, "Instituto de Salud Carlos III"), Spain | 5- IKERBASQUE, Basque Foundation for Science, Bilbao, Spain | 6- Department of Medicine, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain | 7- Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain

Póster: 13



POSTER TOUR

Scavenger receptor MARCO is associated with an immunosuppressive microenvironment and tumor progression in intrahepatic CCA

Aloña Agirre-Lizaso (1) | Maider Huici-Izagirre (1) | Colm J O'Rourke (2) | Ekaterina Zhuravleva (2) | Ana Korosec (3) | Mikel Azkargorta (4,5) | Felix Elortza (4,5) | Sumera I Ilyas (6) | Gregory J Gores (6) | Jesper B Andersen (2) | Gernot Schabbauer (3) | Luis Bujanda (1,4,7) | Pedro M. Rodrigues (1,4,8) | Omar Sharif (3) | Jesus M. Banales (1,4,8,9) | Maria J. Perugorria (1,4,7)

1- Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), San Sebastian, Spain | 2- Biotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark | 3- Institute for Vascular Biology, Centre for Physiology and Pharmacology, Medical University Vienna, Vienna, Austria; Christian Doppler Laboratory for Arginine Metabolism in Rheumatoid Arthritis and Multiple Sclerosis, Vienna, Austria | 4- CIBERehd, Instituto de Salud Carlos III (ISCIII), Madrid, Spain | 5- Proteomics Platform, CIC bioGUNE, ProteoRed-ISCIII, Bizkaia Science and Technology Park, Derio, Spain | 6- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota | 7- Department of Medicine, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), San Sebastian, Spain | 8- IKERBASQUE, Basque Foundation for Science, Bilbao, Spain | 9- Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain

CÁNCER DE HÍGADO

Póster: 14

The remodelling of cholesterol metabolism in hepatocytes delays the development of Colorectal Liver Metastasis

Ane Nieva-Zuluaga (1) | Beatriz Arteta (2) | Mikel Ruiz de Gauna (1) | Mainer Apodaka-Biguri (1) | Idoia Fernández-Puertas (1) | Francisco González-Romero (1) | Beatriz Gómez-Santos (1) | Igotz Delgado (1) | Jesus M Bañales (3,4,5,6) | Andrés Valdivieso (7,8) | Luis Bujanda (3,4) | Igor Aurrekoetxea (1,8) | Xabier Buqué (1) | Patricia Aspichueta (1,3,8)

1- Department of Physiology University of the Basque Country UPV/EHU, Faculty of Medicine and Nursing, Leioa, Spain | 2- Department of Cellular Biology and Histology, University of the Basque Country UPV/EHU, Faculty of Medicine and Nursing, Leioa, Spain | 3- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Carlos III Health Institute), Madrid, Spain | 4- Department of Liver and Gastrointestinal Diseases, Biodonostia Research Institute, Donostia University Hospital, University of the Basque Country UPV-EHU, Donostia-San Sebastian, Spain | 5- IKERBASQUE, Basque Foundation for Science, Bilbao, Spain | 6- Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain | 7- Department of HPB Surgery and Liver Transplantation Unit, Hospital Universitario Cruces, Bilbao, Spain | 8- Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Barakaldo, Spain

Póster: 15

Targeting the E2F/MCM axis in cholangiocarcinoma halts disease progression in experimental models by rewiring cancer lipid metabolism

Mikel Ruiz de Gauna (1) | Kendall Alfaro-Jiménez (1) | Ane Nieva-Zuluaga (1) | Mainer Apodaka-Biguri (1) | Enara Markaide (2) | Laura Izquierdo-Sánchez (2) | Francisco González-Romero (1) | Nerea Muñoz-Llanes (1) | Paul Gómez-Jauregui (1) | Natalia Sainz-Ramírez (1) | Beatriz Gómez-Santos (1) | Xabier Buqué (1) | Igor Aurrekoetxea (1,3) | Igotz Delgado (1) | Idoia Fernández-Puertas (1) | Ainhoa Iglesias-Ara (4) | Colm J. O'Rourke (5) | Pedro M. Rodrigues (2,6,7) | Jesper B. Andersen (5) | Diego F. Calvisi (8) | Ana M. Zubiaga (4) | Jesús M. Bañales (2,6,7,9) | Patricia Aspichueta (1,3,6)

1- University of the Basque Country (UPV/EHU), Faculty of Medicine and Nursing, Department of Physiology, Leioa, Spain | 2- Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain | 3- Biocruces Health Research Institute, Cruces University Hospital, Barakaldo, Spain | 4- University of Basque Country (UPV/EHU), Faculty of Science and Technology, Department of Genetic, Physical Anthropology and Animal Physiology, Leioa, Spain | 5- Department of Health and Medical Sciences, Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark | 6- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III) | 7- IKERBASQUE, Basque Foundation for Science, Bilbao, Spain | 8- Institute for Pathology, Regensburg University, Regensburg, Germany | 9- Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain

CÁNCER DE HÍGADO

Póster: 16

v14.236.1 Modulating the hepatic stellate cell phenotype in liver fibrosis and hepatocellular carcinoma

Noelia Arroyo (1) | Irene Díaz (1,2) | Laura Villamayor (1) | Anabel Rojas (1,2)

1- *1Centro Andaluz de Biología Molecular y Medicina Regenerativa-CABIMER, Universidad Pablo de Olavide, Universidad de Sevilla, Consejo Superior de Investigaciones Científicas (CSIC)* | 2- *2Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM).*

Póster: 17

Dysregulation of RNA-exosome machinery in hepatocellular carcinoma

Víctor J. Fernández Ramírez (1,2,3,4) | Samanta Lozano de la Haba (1,2,3,4) | Natalia Hermán Sánchez (1,2,3,4) | Betsaida Ojeda Pérez (1,2,3,4) | Prudencio Sáez Martínez (1,2,3,4) | Antonio García Estrada (1,2,3,4) | Manuel Rodríguez Peralvarez (1,4,5) | Raúl M. Luque (1,2,3,4) | Juan L. López Cánovas (1,2,3,4) | Manuel D. Gahete (1,2,3,4)

1- *Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004-Cordoba, Spain.* | 2- *Department of Cell Biology, Physiology and Immunology, Universidad de Córdoba, 14004-Córdoba, Spain.* | 3- *Hospital Universitario Reina Sofía, 14004-Córdoba, Spain.* | 4- *Department of Hepatology and Liver Transplantation, Reina Sofía University Hospital, 14004-Córdoba, Spain.* | 5- *CIBER Hepatic and Digestive Diseases (CIBERehd), 14004-Córdoba, Spain.*

Póster: 18

Mecanismos moleculares de la disfunción mitocondrial inducida por Sorafenib en las células tumorales hepáticas

Ester Parras-Martínez (1) | Patricia de la Cruz-Ojeda (1,2,3) | Elena Navarro-Villarán (1,2,3) | José M. García-Pérez (1) | Otto Kučera (4,5) | Marina Fuertes-Agudo (3,6) | Ana Mata (7) | Guillermo López-Lluch (8) | Plácido Navas (8) | Zuzana Červinková (4,9) | Susana Cadenas (7) | Marta Casado (3,6) | Jordi Muntané (2,3,5,10)

1- *Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, España* | 2- *Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, España.* | 3- *Centro de Investigación Biomédica de Enfermedades Hepáticas y Digestivas. (CIBERehd), Madrid, España.* | 4- *Departamento de Fisiología, Charles University, República Checa.* | 5- *COST-European Cooperation in Science & Technology. Mitoeagle Action number: CA15203.* | 6- *Instituto de Biomedicina de Valencia (IBV), CSIC, Jaume Roig 11, 46010 Valencia, Spain.* | 7- *Centro de Biología Molecular "Severo Ochoa" (CSIC/UAM), Madrid, Spain.* | 8- *Departamento de Fisiología, Anatomía y Biología Celular, Universidad Pablo de Olavide, Sevilla, España.* | 9- *COST-European Cooperation in Science & Technology. Mitoeagle Action number: CA15203* | 10- *Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, España.*

CÁNCER DE HÍGADO

Póster: 19

Proteomic study of childhood liver cancer: identification of plasmatic diagnostic and prognostic biomarkers

Álvaro del Río-Álvarez (1,2) | Juan Carrillo-Reixach (1,2) | Mikel Azkargorta (3) | Laura Royo (1) | Christian Vokuhl (4) | Montse Domingo-Sàbat (1) | Rita Alaggio (5) | Ronald de Krijger (6) | Roland Kappler (7) | Marta Garrido (8) | Gabriela Guillen (9) | José Andres Molino (9) | Constantino Sábado (10) | Laura Guerra (11) | Francisco Hernandez (12) | Maria Elena Mateos (13) | Manuel López-Satamaría (12) | Barbara Torres (14) | Maria Pilar Abad (15) | Bajčiová Viera (16) | Piotr Czauderna (17) | Marie Annick Buendia (18) | Keith Wheatley (19) | Felix Elortza (3) | Bruce Morland (20) | Carolina Armengol (1,2)

1- Childhood Liver Oncology Group (c-LOG), Health Sciences Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain. | 2- CIBER, Hepatic and Digestive Diseases, Barcelona, Spain. | 3- Proteomics Platform, CIC bioGUNE - ProteoRed-ISCIII, Derio, Spain. | 4- Section of Pediatric Pathology, Department of Pathology, University Hospital Bonn, Bonn, Germany | 5- Unit of Pathology, Children's Hospital Bambino Gesù IRCCS, Rome, Italy. | 6- Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands. | 7- Department of Pediatric Surgery, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Germany. | 8- Hospital Vall d'Hebron, Pathology Department, Barcelona, Spain. | 9- Hospital Vall d'Hebron, Pediatric Surgery Department, Barcelona, Spain. | 10- Hospital Vall d'Hebron, Pediatric Oncology Department, Barcelona, Spain. | 11- University Hospital La Paz, Pathology Department, Madrid, Spain. | 12- University Hospital La Paz, Pediatric Surgery Department, Madrid, Spain. | 13- Pediatric Oncology Unit, Department of Pediatrics, University Hospital Reina Sofía, Córdoba, Spain. | 14- Medical Oncology Department, Pediatric Oncology Department, University Hospital La Fe, Valencia, Spain | 15- University Hospital Germans Trias i Pujol, Pediatric Surgery Department, Badalona, Spain. | 16- Department of Pediatric Oncology, Childrens University Hospital Brno, Brno, Czech Republic. | 17- Department of Surgery and Urology for Children and Adolescents, Medical University of Gdansk, Gdansk, Poland | 18- INSERM, UMR 1193, Paul-Brousse Hospital, Hepatobiliary Centre F-94800 Villejuif, France | 19- University of Birmingham Clinical Trials Unit, Birmingham, United Kingdom. | 20- Department of Oncology, Birmingham Women's and Children's Hospital, Birmingham, United Kingdom.

CÁNCER DE HÍGADO

Póster: 20**Restoring RORA as a dual strategy to target tumor cells and cancer-associated fibroblasts in intrahepatic cholangiocarcinoma**

Laura Sererols Viñas (1) | Paula Cantallops Vilà (1) | Raquel Martínez García de la Torre (1) | Joana Ferrer (2,3) | Alejandro Forner (2,3) | Loreto Boix (2,3) | Maria Reig (2,3) | Pau Sancho Bru (1,3) | Silvia Affò (1)

1- *Fundació de Recerca Clínic Barcelona – Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS)* | 2- *Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, Hospital Clínic Barcelona, FRCB-IDIBAPS, University of Barcelona, Barcelona, Spain* | 3- *Centro de Investigación Médica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.*

Póster: 21**POSTER TOUR****Inhibition of KLF5 reduces tumor growth and sensitizes to chemotherapy-induced cell death in experimental models of cholangiocarcinoma**

Pedro Miguel Rodrigues (1,2,3) | Oihane Erice (1) | Ana Landa-Magdalena (1) | Nuno André Paiva (1) | Maite García Fernandez-Barrena (4) | Paula Olaizola (1,2) | Ainhoa Lapitz (1,2) | Irene Olaizola (1) | Colm J. O'Rourke (5) | Jesper B. Andersen (5) | Diego F. Calvisi (6) | Mikel Azkargorta (2,7) | Félix Elortza (2,7) | Ibai Goicoechea (8) | Charles H. Lawrie (3,8,9) | Luis Bujanda (1,2) | María Jesús Perugorria (1,2,10) | Jesús María Bañales (1,2,3,11)

1- *Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute – Donostia University Hospital –, University of the Basque Country (UPV/EHU), San Sebastian, Spain* | 2- *National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, “Instituto de Salud Carlos III”), Spain* | 3- *IKERBASQUE, Basque Foundation for Science, Bilbao, Spain* | 4- *Division of Hepatology, CIMA-University of Navarra, Pamplona, Spain* | 5- *Biotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark* | 6- *Institute of Pathology, University of Regensburg, Regensburg, Germany* | 7- *Proteomics Platform, CIC bioGUNE, CIBERehd, ProteoRed-ISCI, Bizkaia Science and Technology Park, Derio, Spain* | 8- *Molecular Oncology group, Biodonostia Research Institute, San Sebastian, Spain* | 9- *Radcliffe Department of Medicine, University of Oxford, UK* | 10- *Department of Medicine, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain* | 11- *Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.*

CÁNCER DE HÍGADO

Póster: 22

Enhancing antitumoral effects of sorafenib:metformin cocktail in Liver cancer cells through nutrient restriction: Insights into metabolic reprogramming and proteomic alterations

Juan Luis López-Cánovas (1,2) | Beatriz Naranjo Martínez (1) | Alberto Diaz-Ruiz (1)

1- Laboratory of Cellular and Molecular Gerontology, Precision Nutrition and Aging Branch, IM-DEA Food Institute, Crta. de Cantoblanco nº 8, E – 28049, Madrid, Spain. | 2- Department of Cell Biology, Physiology and Immunology, University of Cordoba, 14004 Cordoba, Spain.

Póster: 23



POSTER TOUR

Involvement of exosc4 in the progression of hepatocellular carcinoma

Samanta Lozano de la Haba (1,2,3,4) | María Isabel Pozo Relaño (1,2,3,4) | Víctor J. Fernández Ramírez (1,2,3,4) | Natalia Hermán Sánchez (1,2,3,4) | Betsaida Ojeda Pérez (1,2,3,4) | Prudencio Sáez Martínez (1,2,3,4) | Manuel Rodríguez Perálvarez (1,5,6) | Raúl M. Luque (1,2,3,4) | Juan L. López Cánovas (1,2,3,4) | Manuel D. Gahete (1,2,3,4)

1- Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), 14004-Cordoba, Spain. | 2- Department of Cell Biology, Physiology and Immunology, Universidad de Córdoba, 14004-Córdoba, Spain | 3- Hospital Universitario Reina Sofía, 14004-Córdoba, Spain | 4- Department of Hepatology and Liver Transplantation, Reina Sofía University Hospital, 14004-Córdoba, Spain | 5- Department of Hepatology and Liver Transplantation, Reina Sofía University Hospital, 14004- Córdoba, Spain | 6- CIBER Hepatic and Digestive Diseases (CIBERehd), 14004-Córdoba, Spain.

COMPLICACIONES DE LA CIRROSIS
Y TRASPLANTE HEPÁTICO**Póster: 24****Long-term cellular immune response of patients with chronic liver disease vaccinated against COVID-19**

Mariana Moura Henrique (1) | Carolina Santos Palma (1) | André Lopes Simão (1) | Ana Godinho-Santos (1) | Miguel Cardoso (1) | Diogo AE Fernandes (1) | Sofia Carvalhana (2) | Miguel Moura (2) | João Gonçalves (1) | Helena Cortez-Pinto (2,3) | Rui E Castro (1)

1- Research Institute for Medicines (iMed.U LISBOA), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal | 2- Departamento de Gastrenterologia, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal | 3- Clínica Universitária de Gastrenterologia, Faculdade de Medicina, Universidade de Lisboa, Portugal.

**Póster: 25****POSTER TOUR****A novel senolytic nanoformulation targeting the hepatic sinusoid improves hepatic function and fibrosis in experimental models of aging**

David Sanfeliu-Redondo (1) | Vítor Francisco (2) | Inês Tomé (2,3) | Andreia Marques (2,4) | Peio Aristu-Zabalza (1) | João Pitrez (2,5) | Susana Rosa (2) | Lino Ferreira (2,4) | Jordi Gracia-Sancho (1)

1- Liver Vascular Biology Lab. IDIBAPS - Hospital Clínic Barcelona - CIBEREHD. Spain. | 2- CNC- Center for Neurosciences and Cell Biology, University of Coimbra. Portugal. | 3- Faculty of Pharmacy of the University of Coimbra. Portugal. | 4- Faculty of Medicine of the University of Coimbra. Portugal. | 5- Instituto Superior de Engenharia de Coimbra. Portugal.

**Póster: 26****POSTER TOUR****Enhancing regression in a rat model of liver cirrhosis through intermittent fasting**

Pau Rosich (1,2) | Héléne Larrue (1,2,3) | Aina Anton (1,2,4) | Héctor García-Calderó (1,2,4) | Rosa Montañés (1,2) | Genís Campreciós (1,2,4) | Virginia Hernández-Gea (1,2,4,5) | Joan Carles García-Pagán (1,2,4,5)

1- Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-Liver), Barcelona, Catalonia, Spain | 2- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain | 3- 3Department of Hepatology, University Hospital and Toulouse III - Paul Sabatier University, Toulouse, France. | 4- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain | 5- Medicine Department, Faculty of Medicine, Universitat de Barcelona, Barcelona, Catalonia, Spain.

**COMPLICACIONES DE LA CIRROSIS
Y TRASPLANTE HEPÁTICO**

Póster: 27



POSTER TOUR

Evolution of portosystemic collaterals and hyperdynamic circulation after removal of the etiologic agent, in two animal models

Albert Guinart-Cuadra (1) | Héctor García-Calderó (2) | Claudia Pujol (3) | Anna Brujats (3) | Laura Casani (1) | Elisabet Cantó (1) | Rubén Osuna-Gómez (1) | Elisabet Sánchez A (3,4) | Silvia Vidal (1) | Edilmar Alvarado-Tapias (1,3,4) | Candido Villanueva (3,4)

1- Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau), Enfermedades inflamatorias, Barcelona, España. | 2- Liver Vascular Biology Research Group, Hepatic Hemodynamic Lab. IDIBAPS-Hospital Clínic, CIBEREHD, Barcelona, Spain | 3- Hospital Santa Creu i Sant Pau, Instituto de Reserca Sant Pau, Universidad Autónoma de Barcelona, Departamento de Gastroenterología, Barcelona, España. | 4- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, España.

Póster: 28

Hepatic endothelial Endokyne1 as novel pro-fibrotic mediator and theranostic opportunity in chronic liver disease

Ana Martínez-Alcocer (1,2) | Laia Abad-Jordà (2,3) | Peio Aristu-Zabalza (4,5) | Jordi Gracia-Sancho (1,2) | Anabel Fernández-Iglesias (1,2)

1- Liver Vascular Biology Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain | 2- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. | 3- Liver Vascular Biology Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. | 4- Liver Vascular Biology Research Group, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. | 5- Barcelona Liver Bioservices, Barcelona, Spain.

COMPLICACIONES DE LA CIRROSIS
Y TRASPLANTE HEPÁTICO

Póster: 29



POSTER TOUR

Portal vein thrombosis in cirrhosis: a new mechanism of action

Aina Anton (1,2,3) | Genís Campreciós (1,2,3) | Sarah Shalaby (1) | Maria Luisa Botero (1) | Annabel Blasi (1) | Yiliam Fundora (1) | Sergio Barace (4) | Rosa Montañés (1,2) | Héctor García-Calderó (1,2,3) | Lara Orts (1) | Carla Montironi (1) | Pol Olivás (1,3) | Cynthia Bazán (1) | Rommel Zambrano (1) | Olga Tura-Ceide (5,6,7) | Fanny Turon (1,2,3) | Anna Baiges (1,2,3) | Josepmaria Argemí (4) | Joan Carles García-Pagán (1,2,3,8) | Virginia Hernández-Gea (1,2,3,8)

1- *Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-Liver), Barcelona, Spain* | 2- *Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain* | 3- *Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain* | 4- *Centro de investigación Médica Aplicada (CIMA), Universidad de Navarra, Hepatology Program, Pamplona, Spain* | 5- *Department of Pulmonary Medicine, Dr. Josep Trueta University Hospital de Girona, Santa Caterina Hospital de Salt and the Girona Biomedical Research Institute (IDIBGI), Girona, Spain* | 6- *Department of Medical Sciences, Faculty of Medicine, University of Girona, Girona, Spain* | 7- *Biomedical Research Networking Centre on Respiratory Diseases (CIBERES), Madrid, Spain* | 8- *Medicine Department, Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain*

Póster: 30

Restoration of epithelial and vascular intestinal barriers and splanchnic macrophage function mediates the halting of bacterial translocation by propranolol in cirrhotic rats with ascites

Elisa Castillo (1) | Lorena Paule (1) | Leticia Muñoz (1,2) | Manuel Ponce-Alonso (3) | Olaya de Dios (4) | Rosa del Campo (3) | Oscar Pastor (5) | Miguel A Ortega (1,6) | Melchor Álvarez-Mon (1,2,7) | Agustín Albillos (1,2,5)

1- *Departamento de Medicina y Especialidades Médicas, Universidad de Alcalá, Alcalá de Henares, España* | 2- *CIBERehd-Liver and Digestive Diseases Networking Biomedical Research Centre, Spain* | 3- *CIBERinfect- Center for Biomedical Research Network of Infectious Diseases, Spain* | 4- *Instituto de Salud Carlos III: Madrid, Madrid, ES* | 5- *Hospital Universitario Ramón y Cajal IRYCIS, Madrid, Spain* | 6- *CIBER-Center for Biomedical Research Network, Spain* | 7- *Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain.*

**ENFERMEDADES COLESTÁSICAS
Y AUTOINMUNES**

Póster: 31  **POSTER TOUR**

Novel clinical phenotypes in cholestatic DILI, associated drugs, and new prognosis predictive models: analysis of a database of 432 patients developed by collaborative literature review and machine learning support

Poster Tour

Marta Moreno-Torres (1) | Ernesto López (1) | Anna Rapisarda (1) | Jonas Van Ertvelde (2) | Graciela Lopez (3) | Birgitte Lindeman (3) | Thomas Luechtefeld (4) | Eva Serrano Candelas (5) | Emilio Benfenati (6) | Hubert Dir-ven (3) | Mathieu Vinken (2) | Ramiro Jover (7)

1- Joint Research Unit in Experimental Hepatology, University of Valencia, Health Research Institute Hospital La Fe & CIBER of Hepatic and Digestive Diseases, Spain. | 2- Entity of In Vitro Toxicology and Dermato-Cosmetology, Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Belgium | 3- Department of Chemical Toxicology, Norwegian Institute of Public Health, Oslo, Norway | 4- ToxTrack, Baltimore, MD, USA | 5- ProtoQSAR SL, CEEI Parque Tecnológico de Valencia, Spain | 6- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy | 7- Joint Research Unit in Experimental Hepatology, University of Valencia, Health Research Institute Hospital La Fe & CIBER of Hepatic and Digestive Diseases, Spain

Póster: 32

Non-invasive evaluation of progression to primary biliary cholangitis in patients with positive antimitochondrial antibodies

Marta Alonso-Peña (1) | Alvaro Diaz-González (1,2) | Maria Jesus Monte (3,4) | Christie Perelló (4,5) | Paula Iruzubieta (1,2) | Marina Cobreros (2) | Juan Irure (6) | Marcos Lopez-Hoyos (6) | Jose Luis Calleja (4,5) | Jose Juan Garcia Marin (3,4) | Javier Crespo (1,2,4)

1- Research Institute Marques de Valdecilla (IDIVAL), Clinical and Translational Research in Digestive Pathology Group, Santander, Spain | 2- Marques de Valdecilla University Hospital, Gastroenterology and Hepatology, Santander, Spain | 3- University of Salamanca, Experimental Hepatology and Drug Targeting (HEVEPHARM), Salamanca, Spain | 4- Carlos III National Institute of Health, Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Madrid, Spain | 5- Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology and Hepatology, Madrid, Spain | 6- Marques de Valdecilla University Hospital, Immunology, Santander, Spain.

ENFERMEDADES COLESTÁSICAS
Y AUTOINMUNES**Póster: 33****Mitochondrial dynamics and autophagy are disturbed in experimental models of Primary Biliary Cholangitis, contributing to disease pathogenesis**

Irene Lasa (1) | Laura Izquierdo (1,2) | Paula Olaizola (1,2) | Ainhoa Lapitz (1,2) | Luis Bujanda (1,2,3) | María Jesús Perugorria (1,2,3) | Pedro M. Rodrigues (1,2,4) | Jesús Bañales (1,2,4,5)
1- Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute – Donostia University Hospital – University of the Basque Country (UPV/EHU), San Sebastian, Spain | 2- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, “Instituto de Salud Carlos III”), Spain | 3- Departments of Medicine, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, San Sebastian, Spain | 4- IKERBASQUE, Basque Foundation for Science, Bilbao, Spain | 5- Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.

**ENFERMEDADES VASCULARES HEPÁTICAS,
GENÉTICAS, INMUNOLÓGICAS Y DILI**

Póster: 34

Hypertransaminasemia associated with high doses of melatonin in primary progressive multiple sclerosis patients: an uncommon event

Ignacio Bejarano (1,2) | Silvia Jiménez-Jorge (3) | María Ángeles Lobo-Acosta (3) | Ana Isabel Álvarez-López (1,2) | Clara María Rosso-Fernández (3) | Rocío López-Ruiz (4) | Sara Eichau (4) | Juan Luis Ruiz-Peña (4) | Javier Ampuero (2,5) | Iván Cruz-Chamorro (1,2) | Iván Parralejo (1,2) | Vicente Merino-Bohorquez (6) | Manuel Cameán (6) | María Isabel García-Sánchez (7) | Guillermo Izquierdo (8) | Juan Miguel Guerrero (1,2,9) | Manuel Romero-Gómez (2,5) | Patricia Judith Lardone (1,2) | Antonio Carrillo-Vico (1,2)

1- Departamento de Bioquímica Médica y Biología Molecular e Inmunología, Facultad de Medicina, Universidad de Sevilla. Seville, Spain. | 2- Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla. Seville, Spain. | 3- Unit of Clinical Investigation and Clinical Trials (CTU-HUVR), Virgen del Rocío University Hospital. Seville, Spain. | 4- Unit CSUR Multiple Sclerosis, Hospital Universitario Virgen Macarena. Seville, Spain. | 5- Digestive Disease Department, Virgen del Rocío University Hospital. Seville, Spain. | 6- Unidad de Gestión de Farmacia Hospitalaria, Hospital Universitario Virgen Macarena. Seville, Spain. | 7- UGC Neurología. Nodo Hospital Universitario Virgen Macarena, Biobanco del Sistema Sanitario Público de Andalucía. Seville, Spain. | 8- Multiple Sclerosis Unit, Vithas Nisa Sevilla Hospital. Seville, Spain. | 9- Departamento de Bioquímica Clínica, Unidad de Gestión de Laboratorios, Hospital Universitario Virgen del Rocío. Seville, Spain.

Póster: 35

The increased protection of E2f2^{-/-} mice from APAP-induced hepatotoxicity is associated with activation of PPAR α /y and lipophagy

Paul Gomez-Jauregui (1) | Francisco Gonzalez-Romero (1) | Mairer Apodaka-Biguri (1) | Xabier Buque (1) | Maria Crespo (2) | Mariana Mesquita (3,4) | Igor Aurrekoetxea (1,5) | Beatriz Gómez-Santos (1) | Igotz Delgado (1) | Ane Nieva-Zuluaga (1) | Mikel Ruiz de Gauna (1) | Idoia Fernández-Puertas (1) | Nerea Muñoz-Llanes (1) | Natalia Sainz-Ramirez (1) | Kendall Alfaro-Jimenez (1) | Ainhoa Iglesias (6) | Francisco Javier Cubero (3,7,8) | Guadalupe Sabio (2) | Ana Zubiaga (6) | Patricia Aspichueta (1,5,7)

1- Department of Physiology University of the Basque Country UPV/EHU, Faculty of Medicine and Nursing, 48940 Leioa, Spain | 2- Centro Nacional de Investigaciones Cardiovasculares Carlos III, 28029 Madrid, Spain | 3- Institute of Biology, Department of Plant Biology, PPG BMM, University of Campinas (UNICAMP), 13083-970 Campinas, São Paulo, Brazil | 4- Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, 28040 Madrid, Spain | 5- Biocruces Bizkaia Health Research Institute, Cruces University Hospital, 48903 Barakaldo, Spain | 6- Department of Genetic, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, University of Basque Country UPV/EHU, 48940 Leioa, Spain | 7- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBEREHD, Carlos III

ENFERMEDADES VASCULARES HEPÁTICAS,
GENÉTICAS, INMUNOLÓGICAS Y DILI

Health Institute), 28029 Madrid, Spain | 8- Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), 28009 Madrid, Spain.

Póster: 36**Metabolic rewiring of cystic cholangiocytes improves mitochondrial dynamics and bioenergetics ameliorating the pathogenesis of polycystic liver disease in experimental models**

Enara Markaide (1) | Laura Izquierdo Sánchez (1,2) | Mikel Ruiz de Gauna (3) | Xabier Buqué (3) | Pedro M. Rodrigues (1,2,4) | Maria J. Perugorria (1,2,5) | Luis Bujanda (1,2,5) | Patricia Aspichueta (2,3,6) | Jesus M. Banales (1,2,4,7)

1- Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), San Sebastián, Spain | 2- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, "Instituto de Salud Carlos III"), Madrid, Spain | 3- Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain | 4- IKERBASQUE, Basque Foundation for Science, Bilbao, Spain | 5- Department of Medicine, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), San Sebastián, Spain | 6- Biocruces Bizkaia Health Research Institute, Barakaldo, Spain | 7- Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.

Póster: 37**Control compounds used to validate in vitro models of idiosyncratic drug-induced liver injury: a systematic review**

Antonio Segovia Zafrá (1) | Marina Villanueva Paz (1) | Ana Serras (2) | Gonzalo Matilla Cabello (1) | Ana Bodoque García (1) | Daniel Enrique Di Zeo Sánchez (1) | Hao Niu (1) | Ismael Álvarez Álvarez (1) | S Godek (3) | Irina Milisav (3) | José Carlos Fernández Checa (4) | María Isabel Lucena González (1,5) | Francisco Javier Cubero (6) | Joana Miranda (2) | Leonard Nelson (7) | Raúl Andrade Bellido (1)

1- Servicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de la Victoria, IBIMA Plataforma BIONAND, Universidad de Málaga, Málaga, Spain. Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain | 2- Research Institute for Medicines (iMed.U LISBOA), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal | 3- University of Ljubljana, Slovenia, | 4- 5Department of Cell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), CSIC, Barcelona, Spain. | 5- Plataforma de Investigación Clínica y Ensayos Clínicos UICEC-IBIMA, Plataforma ISCIII de Investigación Clínica, Madrid, Spain. | 6- Department of Immunology, Ophthalmology and ORL, Complutense University School of Medicine, Madrid, Spain | 7- Institute for Bioengineering, School of Engineering, Faraday Building, The University of Edinburgh, Scotland, United Kingdom.

HEPATOPATÍA ALCOHÓLICA Y ENFERMEDAD HEPÁTICA METABÓLICA

Póster: 38



POSTER TOUR

CRISPR/Cas9 modification of specific genes in human adipocytes can reduce lipid accumulation in hepatocytes in vitro

Marta Lopez-Yus (1,2,3) | Scott Frendo-Cumbo (4) | Raquel del Moral Bergos (1,2,3) | Maria Pilar Garcia- Sobreviela (1,3) | Vanesa Bernal-Monterde (1,3,5) | Mikael Rydén (4) | Silvia Lorrente-Cebrian (1,6) | Jose M. Arbones-Mainar (1,2,3,7)

1- Adipocyte and Fat Biology Laboratory (AdipoFat), Translational Research Unit, University Hospital Miguel Servet, Zaragoza, Spain | 2- Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain | 3- Instituto de Investigación Sanitaria (IIS) Aragón, 50009, Zaragoza, Spain | 4- Department of Medicine (H7), Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 83, Huddinge, Sweden. | 5- Gastroenterology Department, Miguel Servet University Hospital, 50009, Zaragoza, Spain | 6- Departamento de Farmacología, Fisiología y Medicina Legal y Forense, Universidad de Zaragoza. Instituto Agroalimentario de Aragón (IA2) (Universidad de Zaragoza-CITA), Zaragoza, Spain. | 7- CIBER Fisiopatología Obesidad y Nutrición (CIBERObn), Instituto Salud Carlos III, Madrid, Spain

Póster: 39

Hepatocyte MAVS favors NAFLD progression by inducing TNF α

Eva Novoa (1) | Natália da Silva (1) | Marcos Fernández (1) | Chusa González (1) | Uxia Fernández (1) | Tamara Parracho (1) | Alba Lopez (1) | Rubén Nogueiras (1,2)

1- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain | 2- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Spain

Póster: 40

Is the hepatic fibrosis histological phenotype in pre- and post-menopausal F2/F3 women the same?

Isabel Fernández Lizaranzu (1) | Louis Petitjean (2) | Helena Pastor-Ramirez (1) | Rocío Gallego-Duran (1) | M^aJesús Pareja (1) | Mathieu Petitjean (2) | Manuel Romero-Gómez (1)

1- Instituto de Biomedicina de Sevilla, IBI3/Hospital Universitario Virgen del Rocío/CSIC/Universidad, SeLIVER Group de Sevilla | 2- PharmaNest, Princeton, NJ, USA

Póster: 41

A lupine protein hydrolysate reduces NAFLD markers and alters liver transcriptomic profile in a obese model mice

Eduardo Ponce-España (1,2) | Guillermo Santos-Sánchez (1,2) | Ivan Cruz-Chamorro (1,2) | Ana Isabel Álvarez-López (2) | Jose María Fernández-Santos (3) | Justo Pedroche (4) | María Carmen Millán-Linares (1,4) | Francisco Millán (4) | Patricia Judith Lardone (1,2) | Ignacio Bejarano (1,2) | Antonio Carrillo-Vico (1,2)

HEPATOPATÍA ALCOHÓLICA Y ENFERMEDAD
HEPÁTICA METABÓLICA

1- Departamento de Bioquímica Médica y Biología Molecular e Inmunología, Facultad de Medicina, Universidad de Sevilla | 2- Instituto de Biomedicina de Sevilla, IBI3/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla | 3- Departamento Citología e Histología Normal y Patológica, Universidad de Sevilla | 4- Department of Food & Health, Instituto de la grasa, CSIC

Póster: 42**Study of the role of caspase-2 in metabolic dysfunction-associated steatohepatitis**

Amaya Lopez-Pascual (1,2) | Jose M. Herranz (3,4) | Borja Castelló-Urbe (3) | Elena Adán-Villaescusa (3) | Bruno Sangro (1,2,3) | Marc Cusachs (5) | Carmen Herrero (5) | Matías A. Avila (2,3,4) | Maite G. Fernández-Barrena (2,3,4)

1- Hepatology Unit, CCUN, Navarra University Clinic, Pamplona, Spain. | 2- Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain. | 3- Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain. | 4- CIBERehd, Instituto de Salud Carlos III, Madrid, Spain. | 5- R&D Department, Kintsugi Therapeutics S.L., 08007 Barcelona, Spain.

Póster: 44**POSTER TOUR****Needle biopsy-derived liver organoids enable ALD modelling and drug response**

Silvia Ariño (1,2) | Laura Zanatto (1) | Xavier Thillen (1) | Raquel A Martínez-García de la Torre (1) | Paula Cantalops-Vilà (1) | Laura Sererols-Viñas (1) | Jordi Gratacós-Ginès (1,2,3) | Ana Belén Rubio (1,2,4) | Martina Pérez (1,2,4) | Juan José Lozano (2) | Raquel Ferrer-Lorente (1) | Aina Rill (5) | Zhengqing Xu (1) | Alex Guillamon-Thierry (1) | Elisabetta Mereu (5) | Silvia Affo (1) | Elisa Pose (1,2,4) | Pau Sancho-Bru (1,2)

1- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain | 2- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain | 3- 5Liver Unit, Hospital Clínic, Faculty of Medicine, University of Barcelona, Barcelona, Spain | 4- Liver Unit, Hospital Clínic, Faculty of Medicine, University of Barcelona, Barcelona, Spain | 5- Josep Carreras Leukaemia Research Institute, Barcelona, Spain

Póster: 45**A new translational diet model in rats recapitulates all relevant features of MASH, advanced fibrosis and portal hypertension**

María Martínez Gómez (1) | Imma Raurell Saborit (1,2) | Aurora Barberá Bellés (1) | Claudia Rovira Belbeny (1) | Joan Genescà Ferrer (1,2) | Juan Manuel Pericàs Pulido (1,2) | María Martell Pérez-Alcalde (1,2)

1- Laboratorio De Enfermedades Hepáticas, Departamento de Medicina Interna, Hospital Universitari Vall d'Hebron, Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, España | 2- Centro De Investigación Biomédica En Red De Enfermedades Hepáticas y Digestivas, Instituto De Salud Carlos III, Madrid, España

HEPATOPATÍA ALCOHÓLICA Y ENFERMEDAD HEPÁTICA METABÓLICA

Póster: 46

Insights into the mechanisms underlying the anti-steatotic action of Rilpivirine in an experimental model of MASLD: hepatic lipidome and effects in the adipose tissue

Isabel Fuster-Martínez (1,2) | Ana M. Benedicto (1,2) | Pepa Kecheva (1) | Juan V. Esplugues (1,2,3) | Nadezda Apostolova (1,2,3) | Ana Blas-García (2,3,4)

1- Department of Pharmacology, University of Valencia, Valencia, Spain | 2- Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), University Hospital Doctor Peset, Valencia, Spain | 3- Biomedical Research Networking Center in Hepatic and Digestive Diseases (CIBERehd), Spain | 4- Department of Physiology, University of Valencia, Valencia, Spain.

Póster: 47

Biomarkers of endothelial dysfunction in patients with Non-Alcoholic Fatty Liver Disease

Rocío Montero Vallejo (1) | Rocío Gallego Durán (1) | Douglas Maya (1) | Sheila Gato (1) | Vanessa García Fernández (1) | Rocío Muñoz Hernández (1) | Antonio Gil (1) | Ángela Rojas (1) | Mayte García Fernández de Barrena (2) | Jose Maria Herranz (2) | Virginia Hernández Gea (3) | Genis Campreciós (3) | M^a Carmen Rico (1) | Manuel Romero Gómez (1) | Javier Ampuero Herrojo (1)

1- Servicio de Aparato Digestivo, Hospital Universitario Virgen del Rocío; SeLiver Group, Instituto de Biomedicina de Sevilla (HUVR/CSIC/US), Departamento de Medicina Universidad de Sevilla; CIBEREHD, Sevilla. | 2- Programa de Hepatología. CIMA. Universidad de Navarra. CIBEREHD. Pamplona, España. | 3- Unidad de Hemodinámica Hepática. Servicio de Hepatología, Hospital Clínic, Universidad de Barcelona, IDIBAPS, CIBEREHD, Barcelona, España.

Póster: 48

Somatostatin system characterisation unveils the potential therapeutic role of neuropeptide Y receptor GPR107 in chronic liver disease

Antonio García-Estrada (1,2,3,4) | Natalia Hermán-Sánchez (1,2,3,4) | Prudencio Sáez-Martínez (1,2,3,4) | Manuel Rodríguez-Perálvarez (1,5,6) | Raúl M. Luque (1,2,3,4) | Juan L. López-Cánovas (1,2,3,4) | Manuel D. Gahete (1,2,3,4)

1- Maimónides Institute of Biomedical Research of Córdoba (IMIBIC), 14004, Córdoba, Spain | 2- Department of Cell Biology, Physiology and Immunology, University of Córdoba, 14004, Córdoba, Spain | 3- Reina Sofia University Hospital, 14004, Córdoba, Spain | 4- CIBER Physiopathology of Obesity and Nutrition (CIBERObn), 14004, Córdoba, Spain | 5- Department of Hepatology and Liver Transplant, Reina Sofia University Hospital, 14004, Córdoba, Spain | 6- CIBER Hepatic and Digestive Diseases (CIBERehd), 14004, Córdoba, Spain.

HEPATOPATÍA ALCOHÓLICA Y ENFERMEDAD
HEPÁTICA METABÓLICA

Póster: 49



POSTER TOUR

Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates non-alcoholic steatohepatitis by improving mitochondrial function

Poster Tour

Tamara Parracho (1) | Maria J. Gonzalez-Rellan (1,2) | Violeta Heras (1) | Marcos F. Fondevila (1,2) | Eva Novoa (1,2) | Natalia Lima (1) | Ana Senra (1) | Carlos Dieguez (1,2) | Ruben Nogueiras (1,2,3)

1- Department of Physiology, CIMUS, University of Santiago de Compostela, Spain | 2- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Spain | 3- Galicia Agency of Innovation (GAIN), Xunta de Galicia, Santiago de Compostela, Spain.

Póster: 50

NASH patients with elevated E2F2 levels exhibit vulnerability to disease progression due to increased DNA damage-associated metabolic dysfunction

Idoia Fernández-Puertas (1) | Beatriz Gómez-Santos (1) | Paul Gómez-Jauregui (1) | Nerea Muñoz-Llanes (1) | Natalia Sainz-Ramirez (1) | Kendall Alfaro-Jiménez (1) | Ane Nieva-Zuluaga (1) | Mikel Ruiz de Gauna (1) | Maider Apodaka Biguri (1) | Francisco Gonzalez-Romero (1) | Igotz Delgado (1) | Igor Aurrekoetxea (1,2) | Lorena Mosteiro (2) | Gaizka Errazti (2) | Sonia Gaztambide (2) | Luis Castaño (2) | Luis Bujanda (3,4) | Jesus M Banales (3,4,5) | Xabier Buque (1) | Ana M Zubiaga (6) | Patricia Aspichueta (1,2)

1- Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain. | 2- Biocruces Bizkaia Health Research Institute, Barakaldo, Spain. | 3- Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute-Donostia University Hospital, University of the Basque (UPV/EHU), San Sebastian, Spain. | 4- Biomedical Research Networking Center in Hepatic and Digestive Diseases (CIBERehd), Madrid, Spain. | 5- Ikerbasque, Basque Foundation for Science, Bilbao, Spain. | 6- Department of Genetics, Physical Anthropology and Animal Physiology, Faculty of Science and Technology, University of Basque Country UPV/EHU, Leioa, Spain.

Póster: 51

Placental hormones programme maternal hepatic metabolism across pregnancy with post-partum effects

Jorge Lopez-Tello (1) | Ruben Bermejo-Poza (2) | Esteban Salazar-Petres (1) | Efthimia R Christoforou (1) | Hannah EJ Yong (1) | Emma Siragher (1) | Almudena Cabezas (2) | Jesus De la Fuente (2) | Tina Napso (1) | Russell Hamilton (1) | Ionel Sandovici (1,3,4) | Vicente Perez-Garcia (5) | Miguel Constanca (1,3,4) | Amanda Sferruzzi-Perri (1)

1- Centre for Trophoblast Research, Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge CB2 3EG, UK | 2- Department of Animal Production, Veterinary School, Complutense University of Madrid, Avenida Puerta de Hierro s/n, 28040 Madrid, Spain | 3- Department of Obstetrics and Gynaecology and National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge CB2 0SW, UK | 4- Medical Research

HEPATOPATÍA ALCOHÓLICA Y ENFERMEDAD HEPÁTICA METABÓLICA

Council (MRC) Metabolic Diseases Unit, Wellcome-MRC Institute of Metabolic Science and, University of Cambridge, Cambridge CB2 0QQ, UK | 5- Centro de Investigación Príncipe Felipe, Eduardo Primo Yúfera, Spain.

Póster: 52  **POSTER TOUR**

Perivascular macrophages in the adipose tissue contribute to non alcoholic fatty liver disease

Celia Martínez Sánchez (1,2) | Xènia Almodovar (1) | Anna Soria (3) | Isabel Graupera (1,2,3) | Mar Coll (4)

1- Instituto de Investigaciones Biomédicas August Pi i Sunyer, Barcelona, Spain | 2- Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas. | 3- Liver Unit, Hospital Clinic Barcelona, Spain | 4- Universidad de Medicina Barcelona, Spain.

Póster: 53

Endothelial and platelet-derived microvesicles as a Biomarker of Cardiovascular risk in patients with metabolic dysfunction associated fatty liver disease (MAFLD)

Sheila Gato Zambrano (1) | Rocío Muñoz Hernández (1) | Rocío Montero Vallejo (1) | María del Carmen Rico (1) | Vanessa García Fernández (1) | Ángela Rojas (1) | Antonio Gil Gómez (1) | Javier Gallego (1) | Rocío Gallego Durán (1) | Douglas Maya Miles (1) | Javier Ampuero (1) | Manuel Romero Gómez (1)

1- Servicio de Aparato Digestivo, Hospital Universitario Virgen del Rocío; SeLiver Group, Instituto de Biomedicina de Sevilla (HUVR/CSIC/US), Departamento de Medicina Universidad de Sevilla; CIBEREHD, Sevilla.

Póster: 54

Role of kynurenine in the pathogenesis of metabolic associated fatty liver disease

Alvaro Santos-Laso (1) | Paula Iruzubieta (1,2) | Carolina Jiménez-González (1) | David Merino (3) | Laura Izquierdo-Sanchez (2,4) | María Gutiérrez-Larrañaga (5) | Paula Do Rego (3) | Enara Markaide (4) | Juan M Medina (1) | María Teresa Arias-Loste (1,2) | Lorena Cayon (1,2) | Ana Álvarez-Cancelo (1) | Sara Arias-Sánchez (1) | Jesus M Banales (2,4,6) | Marcos López-Hoyos (5) | Javier Crespo (1,2)

1- Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, Santander, Spain. | 2- National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd). ISCIII. | 3- Flow cytometry and cell isolation unit, IDIVAL, Santander, Spain. | 4- Department of Liver and Gastrointestinal Diseases, Biodonostia Research Institute – Donostia University Hospital –, University of the Basque Country (UPV/EHU), San Sebastian, Spain. | 5- Immunology Department, Marqués de Valdecilla University Hospital, Autoimmunity and Transplantation Research Group, IDIVAL, Santander, Spain. | 6- Ikerbasque. Basque Foundation for Science.

HEPATOPATÍA ALCOHÓLICA Y ENFERMEDAD
HEPÁTICA METABÓLICA**Póster: 55** POSTER TOUR**Comprehensive analysis of epigenetic and epitranscriptomic genes expression in human NAFLD**

Jose M. Herranz (1,2) | Amaya López-Pascual (3,4) | Alex Clavería-Cabello (1) | Iker Uriarte (1,2) | M. Ujúe Latasa (1) | Ainara Irigaray-Miramon (1) | Elena Adán-Villaescusa (1) | Borja Castelló-Urbe (1) | Bruno Sangro (2,3,4) | María Arechederra (1,2,4) | Carmen Berasain (1,2) | Matías A. Avila (1,2,4) | Maite G. Fernandez-Barrena (1,2,4)

1- Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain. | 2- CIBERehd, Instituto de Salud Carlos III, Madrid, Spain. | 3- Hepatology Unit, CCUN, Navarra University Clinic, Pamplona, Spain. | 4- Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain.

Póster: 56**Hepatocyte-specific Sucnr1 deletion impacts gluconeogenesis and NASH-related steatosis**

Anna Marsal-Beltran (1,2,3) | Laura Salmerón-Pelado (1) | Aleix Ribas-Latre (1,3) | M-Mar Rodríguez-Peña (1,2) | Catalina Núñez-Roa (1,2) | Maria Repollés-de-Dalmou (1,2,3) | Eva Novoa (4,5) | Rubén Nogueiras (4,5) | Joan Vendrell (1,2,3) | Victòria Ceperuelo-Mallafré (1,2,3) | Sonia Fernández-Veledo (1,2,3)

1- Research Unit. University Hospital of Tarragona Joan XXIII, Pere Virgili Health Research Institute (IISPV), Tarragona, Spain. | 2- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) - Instituto de Salud Carlos III, Madrid, Spain. | 3- Rovira i Virgili University, Tarragona, Spain. | 4- Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela- Instituto de Investigación Sanitaria, Santiago de Compostela, Spain. | 5- CIBER de Fisiopatología de la Obesidad y Nutrición (CIBEROBN) - Instituto de Salud Carlos III, Madrid, Spain.

Póster: 57**Single-cell RNA sequencing in DIAMOND mice reveals differentially regulated pathways specifically associated with the transition from simple steatosis towards NASH**

Rocío Gallego-Durán (1,2) | Douglas Maya-Miles (1,2) | Ignacio Benedicto (3) | Jose María Herranz (2,4) | Lucía López-Bermudo (5,6) | Elena Vázquez-Ogando (7) | Rocío Montero-Vallejo (1,2) | María José Robles-Frías (8) | Blanca Escudero-López (5,6) | Antonio Cárdenas-García (5,6) | Ana Quintas (9) | Elena Blázquez-López (2,7) | Francisco Javier Cubero (2,3) | Javier Vaquero (2,7) | Yulia Nefzorova (3) | Maite Fernández-Barrena (2,4) | Matías Ávila (2,4) | Jordi Gracia-Sancho (2) | Rafael Bañares (2,7) | Francisco Martín-Bermudo (5,6) | Manuel Romero-Gómez (1,2) | Javier Ampuero (1,2)

1- UCM Digestive Diseases, Hospital Universitario Virgen del Rocío; SeLiver Group, Instituto de Biomedicina de Sevilla (HUVR/CSIC/US), Departamento de Medicina Universidad de Sevilla,

HEPATOPATÍA ALCOHÓLICA Y ENFERMEDAD HEPÁTICA METABÓLICA

Sevilla, Spain | 2- CIBEREHD- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Spain | 3- Departamento de Inmunología, Oftalmología y ORL, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain | 4- Program of Hepatology, Centre of Applied Medical Research (CIMA), University of Navarra, Spain | 5- Centro Andaluz de Biología Molecular y Medicina Regenerativa-CABIMER, Universidad Pablo de Olavide, Universidad de Sevilla, Consejo Superior de Investigaciones Científicas (CSIC), Spain | 6- CIBERDEM- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Spain | 7- HepatoGastro Lab, Servicio de Ap. Digestivo del HGU Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Spain | 8- Pathology Department, Hospital Universitario Virgen del Rocío, Spain | 9- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Spain

Póster: 58



POSTER TOUR

CDKN1A, a novel marker for diagnosis and staging of NAFLD/NASH?

Alejandro H. Gutiérrez (1) | Arantza Lamas-Paz (1,2) | Douglas Maya (3,4) | Gonzalo Jorquera (5,6) | Mariana Mesquita (1,7) | Feifei Guo (1,8) | Laura Morán-Blanco (1) | Raquel Benedé-Ubieto (1,9) | Olga Estévez-Vázquez (1) | Marina S Mazariegos (1) | Elena Vázquez-Ogando (4,10,11) | Elena Blázquez-López (4,10,11) | Iris Asensio (4,10,11) | Xabier Buqué (4,12) | Maider Apodaka (4,12) | María Isabel Peligros (13) | Javier Vaquero (4,10,11) | Rafael Bañares (4,10,11) | Teresa C. Delgado (14) | María Luz Martínez-Chantar (4,14) | Patricia Aspichueta (4,12) | Eduardo Martínez-Naves (1,2) | Carlos Sanz-García (1) | Rocío Gallego-Durán (3,4) | Javier Ampuero (3,4) | Manuel Romero-Gómez (3,4) | Albert Gilbert-Ramos (4,15) | Sergi Guixé-Muntet (4,15) | Anabel Fernández-Iglesias (4,15) | Gracia-Sancho J (4,15,16) | Mar Coll (4,17) | Isabel Graupera (4,17,18) | Pere Ginès (4,17,18) | Andrea Ciudin (19) | Jesús Rivera-Esteban (20) | Juan M. Pericàs (4,21) | María José Frutos (22) | Bruno Ramos Molina (4,23) | José María Herranz (4,24) | Matías A. Ávila (4,24,25) | Pere Puigserver (26,27) | Yulia A. Nevzorova (1,4,11) | Francisco Javier Cubero (1,4,11)

1- Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, Madrid, Spain | 2- 12 de Octubre Health Research Institute (imas12), Madrid, Spain | 3- Instituto de Biomedicina de Sevilla/Hospital Universitario Virgen del Rocío/Universidad de Sevilla, Sevilla, Spain | 4- Centre for Biomedical Research, Network on Liver and Digestive Diseases (CIBEREHD), Madrid, Spain | 5- Institute of Nutrition and Food Technology (INTA), Universidad de Chile, Santiago, Chile | 6- Center of Neurobiology and Integrative Physiopathology (CENFI), Science Faculty, Universidad de Valparaíso, Valparaíso, Chile | 7- State University of Campinas, Campinas, Sao Paulo, Brasil | 8- Department of Obstetrics and Gynaecology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China | 9- Department of Genetics, Microbiology and Physiology, Complutense University School of Biology, Madrid, Spain | 10- Servicio de Aparato Digestivo, Hospital General Universitario Gregorio Marañón, Madrid, Spain | 11- Health Research Institute Gregorio Marañón (IISGM), Madrid, Spain | 12- Department of Physiology, Basque Country University (UPV/EHU) School of Medicine and Nursing, Bilbao, Spain | 13- Servicio

HEPATOPATÍA ALCOHÓLICA Y ENFERMEDAD
HEPÁTICA METABÓLICA

de Anatomía Patológica, Hospital General Universitario Gregorio Marañón, Madrid, Spain | 14- Liver Disease Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, Spain | 15- Liver Vascular Biology Research Group, IDIBAPS, Barcelona, Spain | 16- Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland | 17- Laboratorio de Plasticidad de Células Hepáticas y Reparación de Tejidos, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain | 18- Liver Unit, Hospital Clinic, Barcelona, Spain | 19- Endocrinology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute for Research (VHIR), Barcelona, Spain | 20- Liver Unit, Internal Medicine Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute for Research (VHIR), Barcelona, Spain | 21- Liver Unit, Internal Medicine Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute for Research (VHIR), Barcelona, Spain | 22- Department of General and Digestive System Surgery, Virgen de la Arrixaca University Hospital, Murcia, Spain | 23- Laboratorio de Obesidad y Metabolismo, Instituto de Investigación Biomédica de Murcia (IMIB-Arrixaca), Murcia, Spain | 24- Hepatology Programme, Centre for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain | 25- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain | 26- Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA | 27- Department of Cell Biology, Harvard Medical School, Boston, MA, USA

Póster: 59**Non-sense mediated decay as a potential source of early biomarkers in metabolic dysfunction-associated steatotic liver disease and hepatocarcinoma**

Betsaida Ojeda-Pérez (1,2,3,4) | Natalia Hermán-Sánchez (1,3,4,5) | Antonio García-Estrada (1,3,4,5) | Manuel Rodríguez-Peralvarez (1,3,6,7) | Raúl M. Luque (1,2,3,4) | Juan L. López-Cánavas (1,3,4,5) | Manuel D. Gahete (1,2,3,4)

1- Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain. | 2- Department of Cell Biology, Physiology and Immunology, University of Cordoba, 14004 Cordoba, Spain. | 3- Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain. | 4- CIBER Physiopathology of Obesity and Nutrition (CIBERObn), 14004 Cordoba, Spain. | 5- Department of Cell Biology, Physiology and Immunology, University of Cordoba, 14004 Cordoba, Spain | 6- Department of Hepatology and Liver Transplantation, Reina Sofia University Hospital, 14004 Córdoba, Spain. | 7- CIBER Hepatic and Digestive Diseases (CIBERehd), 14004 Córdoba, Spain.

**HEPATOPATÍA ALCOHÓLICA Y ENFERMEDAD
HEPÁTICA METABÓLICA**

Póster: 60

Glutaminolysis and steatosis to steatohepatitis transition: Role of glutaminase

Vanessa García-Fernández (1) | Antonio Gil-Gómez (1) | Ángela Rojas (1,2) | Rocío Muñoz-Hernández (1,2) | Sheila Gato (1,2) | Rocío Montero-Vallejo (1,2) | Rocío Gallego-Durán (2,3) | Douglas Maya-Miles (1,2) | María del Carmen Rico (1,2,4) | Javier Ampuero (1,2,4) | Manuel Romero-Gómez (1,2,4)

"1- Seliver Group. Instituto De Biomedicina De Sevilla (IBiS), Hospital Universitario Virgen Del Rocío/CSIC/Universidad De Sevilla | 2- Centro De Investigación Biomédica En Red De Enfermedades Hepáticas y Digestivas (CIBEREHD) | 3- 1. Seliver Group. Instituto De Biomedicina De Sevilla (IBiS), Hospital Universitario Virgen Del Rocío/CSIC/Universidad De Sevilla | 4- UCM Digestive Diseases. Hospital Universitario Virgen Del Rocío, Sevilla, Spain"

Póster: 61

NAFLD associated with cardiac dysfunction in a mouse model of heart failure with preserved ejection fraction

Rebeca Pérez-Cabeza de Vaca, Luis Luévano-Martínez, Judith Bernal-Ramírez, Abraham Méndez-Fernández, Néstor Rubio-Infante, Omar Lozano, Gerardo García-Rivas*. (1)

1- Medicina experimental y terapias avanzadas. Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud and The Institute for Obesity Research.

GENERAL INFORMATION

COURSE DIRECTORS:

Edilmar Alvarado, Hospital de la Santa Creu i Sant Pau (Barcelona)

Manuel D. Gahete, IMIBIC (Córdoba)

Douglas Maya, Instituto de Biomedicina de Sevilla (Sevilla)

ORGANIZING SECRETARIAT:




Oasis Events & Travel Solutions
C/ Sor Ángela de la Cruz, 8. 1º A
28020 - Madrid (Spain)
☎ +34 91 5551119
Email: aeeh@viajesoasis.com
Web site: www.viajesoasis.com

MEETING VENUE:

Institute of Biomedicine of Sevilla: IBIS 
C. Antonio Maura Montaner, 41013 Sevilla

Central Courtyard Of Virgen del Rocio Hospital 
Av. Manuel Siurot, 43, 41013 Sevilla

IBIS Terrace 
C. Antonio Maura Montaner, 41013 Sevilla



GENERAL INFORMATION

MEETING DATES:

October, 5th & 6th, 2023

SECRETARIAT SCHEDULE:

Thursday October 5, 2023 / From 10.00 to 20.00

Friday October 6, 2023 / From 08.00 to 14.30

FEE INCLUDES:

- Access to all scientific sessions
- Lunch
- Coffee breaks scheduled in the programme
- One full set with Meeting documentation
- Certificate of attendance
- Meeting Dinner

REGISTRATION PROCEDURES AND GUIDELINES:

Registration can be made as follows:

- Online: Web site: www.aeeh.es

BADGE:

Identification badge will be necessary for admission to the scientific sessions and social events.

DELIVERY OF MULTIMEDIA MATERIAL:

All presentations must be delivered at least one hour before the start of each session. The meeting room will be equipped with a multimedia projector for computer projection, the only program accepted is PowerPoint, **any other audiovisual material will be provided/accepted**. We strongly request all speakers refrain from using their laptop to avoid system compatibility problems.

SCAN THIS QR CODE TO REQUEST YOUR CERTIFICATE OF ATTENDANCE:



ACKNOWLEDGEMENTS

The Spanish Foundation for the Study of the Liver (FEEH/AEEH) is grateful to the following sponsor for its continued support of this important educational and scientific activity.



Organized by:



AEEH
Asociación Española
para el Estudio del Hígado

Endorsed:



Oasis Events & Travel Solutions
C/ Sor Ángela de la Cruz, 8. 1A
28020 - Madrid (Spain)
Phone: +34 915551119
Email: aeeh@viajesoasis.com